1-3 of 3
Adam Bagg
Close
Sort by
Journal Articles

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era

Daniel J. Landsburg, Jennifer JD Morrissette, Sunita D. Nasta, Stefan K. Barta, Stephen J. Schuster, Jakub Svoboda, Elise A. Chong, Adam Bagg
Journal: Blood Advances
Blood Adv (2023) 7 (23): 7243–7253.
https://doi.org/10.1182/bloodadvances.2023011384
Published: 2023
Includes: Supplemental data
Journal Articles

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes

Clinical Trials & Observations
Sheila K. Pierson, Megan S. Lim, Gordan Srkalovic, Joshua D. Brandstadter, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Natalie Mango, Criswell Lavery, Bridget Austin, Daisy Alapat, Mary Jo Lechowicz, Adam Bagg, Hongzhe Li, Corey Casper, Frits van Rhee, David C. Fajgenbaum
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6652–6664.
https://doi.org/10.1182/bloodadvances.2023010745
Published: 2023
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019